medigraphic.com
ISSN 1561-302X (Print)

2020, Number 1

<< Back Next >>

Rev cubana med 2020; 59 (1)

Metastasis: a milestone for knowledge, a challenge for science

Guerra GA, Silva E, Montero S, Rodríguez DJ, Mansilla R, Nieto VJM

Language: Spanish
References: 73
Page: 1-20
PDF size: 290.67 Kb.


ABSTRACT

Introduction: Cancer metastasis is the transfer of tumor cells from one organ to another through a series of interrelated sequential multi-steps. This process is one of the main challenges in cancer treatment due to the biological heterogeneity. The metastasis process is considered the main cause of death in this disease, accounting for more than 90% of cancer deaths.
Objective: To identify the most recent advances on solid tumor metastasis and the association with epithelial-mesenchymal transition (EMT) in relation to the evolution and emergence of cancer.
Method: A non-systematic review was carried out of the most significant studies on the subject, published in Web of Science, Pubmed, Ebsco, Scopus and Infomed.
Conclusions: Metastasis is the main cause of cancer death, so understanding the bases of the mechanism for metastatic tumor formation will allow for more effective therapies.


REFERENCES

  1. Kitano H, Kitano H. Systems Biology : A Brief Overview. Science. 2017;295(5560):1662-4.

  2. Hanahan D, Weinberg RA. The Hallmarks of Cancer Review Douglas. Cell. 2000;100(7):57-70.

  3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.

  4. Talmadge JE, Fidler IJ. AACR centennial series: The biology of cancer metastasis: Historical perspective. Cáncer Res. 2010;70(14):5649-69.

  5. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging Biological Principles of Metastasis. Cell. 2017;168(4):670-91.

  6. Guerra A, Rodríguez DJ, Silva E, Betancourt-mar JA, Cocho G, Nieto-villar RMJM. Chronotherapy of cancer: Epithelial-Mesenchymal transition. MOJ Gerontol Ger. 2019;4(4):124-27. doi: 10.15406/mojgg.2019.04.00192

  7. Folkman J. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine. 1971;285:1182-86.

  8. Nagy JA, Dvorak HF. Heterogeneity of the tumor vasculature: The need for new tumor blood vessel type-specific targets. Clin Exp Metastasis. 2012;29(7):657-62.

  9. Kalluri R, Weinberg RA. Review series The basics o epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-8.

  10. Salami J, Crews CM. Waste disposal-An attractive strategy for cancer therapy. Science. 2017;355(6330):1163-7.

  11. Yang J, Weinberg RA. Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis. Dev Cell. 2008;14(6):818-29.

  12. Scheel C, Weinberg RA. Cancer stem cells and epithelial–mesenchymal transition: concepts and molecular links. In Seminars in cáncer biology. Academic Press. 2012;22(5- 6):396-403.

  13. Suhail Y, Cain MP, Vanaja K, Kurywchak PA, Levchenko A, Kalluri R, et al. Systems Biology of Cancer Metastasis. Cell Syst. 2019;9(2):109-27.

  14. Houg DS, Bijlsma MF. The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. Mol Cancer. 2018;17(1):1-18.

  15. Riggi N, Aguet M, Stamenkovic I. Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment. Annu Rev Pathol Mech Dis. 2017;13(1):117-40.

  16. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;133:571-3.

  17. Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodríguez G, et al. Premetastatic niches: Organ-specific homes for metastases. Nat Rev Cancer. 2017;17(5):302- 17.

  18. Psaila B, Lyden, D. The metastatic niche: adapting the foreign soil. Nature Reviewa Cancer. 2009(9):285-293. Disponible en: https://www.nature.com/articles/nrc2621

  19. Mittal V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018;13:395-412.

  20. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580-84.

  21. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT. Cell. 2016;166:21-45.

  22. Gupta GP, Massagué J. Cancer Metastasis: Building a Framework. Cell. 2006;127(4):679-95.

  23. Jolly MK, Boareto M, Huang B, Jia D, Lu M, Onuchic JN, et al. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front Oncol. 2015;5:1-19.

  24. Grosse Wilde A, D’Hérouël AF, McIntosh E, Ertaylan G, Skupin A, Kuestner RE, et al. Stemness of the hybrid epithelial/mesenchymal state in breast cancer and its association with poor survival. PLoS One. 2015;10(5):1-28.

  25. Calegari F, Waskow C. Cells Stem Cells Stem Cells Stem Cells. Vol. 2, Principles of Regenerative Medicine. 2013. 109-113 p.

  26. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis. AJA Opinion: The origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer. 2005;5:899-904 . doi: 10.1038/nrc1740

  27. Bocci F, Levine H, Onuchic JN, Jolly MK. Deciphering the Dynamics of Epithelial- Mesenchymal Transition and Cancer Stem Cells in Tumor Progression. Curr Stem Cell Reports. 2019;5(1):11-21.

  28. Biddle A, Gammon L, Liang X, Costea DE, Mackenzie IC. Phenotypic Plasticity Determines Cancer Stem Cell Therapeutic Resistance in Oral Squamous Cell Carcinoma. EBioMedicine. 2016;4:138-45.

  29. Fustaino V, Presutti D, Colombo T, Cardinali B, Papoff G, Brandi R, et al. Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines. Oncotarget. 2017;8(61):103340-63.

  30. Andriani F, Bertolini G, Facchinetti F, Baldoli E, Moro M, Casalini P, et al. Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells. Mol Oncol. 2016;10(2):253-71.

  31. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-tomesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525-30.

  32. Ward PS, Thompson CB. Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. Cancer Cell. 2012;21(3):297-308.

  33. Hofschröer V, Koch KA, Ludwig FT, Friedl P, Oberleithner H, Stock C, et al. Extracellular protonation modulates cell-cell interaction mechanics and tissue invasion in human melanoma cells. Nat Publ Gr. 2017;(July 2016):1-13.

  34. Coffelt SB, Wellenstein MD, De Visser KE. Neutrophils in cancer: Neutral no more. Nat Rev Cancer. 2016;16(7):431-46.

  35. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLOS Biol. 2004;2(2):7.

  36. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315(26):1650-9.

  37. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146.

  38. Schaijik B Van, Wickremesekera AC, Mantamadiotis T, Kaye AH. Circulating tumor stem cells and glioblastoma : A review Circulating tumor stem cells and glioblastoma : A review. J Clin Neurosci. 2019;(61):5-9.

  39. Aceto N, Toner M, Maheswaran S, Haber DA. En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition. Trends in Cancer. 2015;1(1):44-52.

  40. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576-90.

  41. Reymond N, D’Água BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer. 2013;13(12):858-70.

  42. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat. Med. 2000;6(1):100-2.

  43. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer. 2007,7:834-46.

  44. Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc. Natl. Acad. Sci. USA. 2011,108:12396-400.

  45. Boudreau N, Bissell MJ. Extracellular matrix signaling: Integration of form and function in normal and malignant cells. Curr. Opin. Cell Biol. 1998,10:640-46.

  46. Giancotti FG. Mechanisms governing metastatic dormancy and reactivation. Cell. 2013;155(4):750-64.

  47. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432(7015):307-15.

  48. Summers MA, McDonald MM, Croucher PI. Cancer Cell Dormancy in Metastasis. Cold Spring Harbor Perspectives in Medicine. 2019[acceso: 16/08/2019]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31548220

  49. Osisami M, Keller E. Mechanisms of Metastatic Tumor Dormancy. Journal of Clinical Medicine. 2013,2(3):136-50.

  50. El-Kenawi A, Hänggi, K, Ruffell B. The Immune Microenvironment and Cancer Metastasis. Cold Spring Harbor Perspectives in Medicine, 2019[acceso: 16/08/2019]. Disponible http://perspectivesinmedicine.cshlp.org/content/early/2019/09/09/cshperspect.a037424.full.p df+html

  51. Allen M, J Jones, Jekyll and Hyde: the role of the microenvironment on the progression of cáncer; J. Pathol. 2010;223:162-76.

  52. Yaromina A, Krause M, Baumann M. Individualization of cancer treatment from radiotherapy perspective. Molecular Oncology, 2012;6(2):211-21.

  53. Possemato R, KM Marks, YD Shaul, ME Pacold, Kim K, Birsoy, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476:346-50.

  54. Anderson ARA, Chaplain MAJ, Newman EL, Steele RJC, Thompson AM. Mathematical Modelling of Tumour Invasion and Metastasis. Journal of Theoretical Medicine. 2000;2(2):129-54.

  55. Mormont MC, F. Levi. Cancer chronotherapy: principles, applications, and perspectives. Cancer. 2003;97(1):155-69.

  56. Magi S, Iwamoto K, Okada-Hatakeyama M. Current status of mathematical modeling of cancer–From the viewpoint of cancer hallmarks. Current Opinion in Systems Biology. 2017;2:39-48.

  57. Simeoni C, Dinicola S, Cucina A. Systems biology approach and mathematical modeling for analyzing phase-space switch during epithelial-mesenchymal transition. In Systems Biology. 2018;95-123.

  58. Lévi F. Circadian chronotherapy for human cancers. The lancet oncology. 2001;2(5):307315.

  59. Misset JL, F Levi. Chronotherapy with 5-fluorouracil and other drugs in gastrointestinal malignancies. Chronotherapy Group of the European Organization for Research and Treatment of Cancer. in Seminars in oncology. Pubmed. 2000[acceso: 16/08/2019]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11049036

  60. Litinski M, Scheer FA, Shea SA. Influence of the circadian system on disease severity. Sleep medicine clinics. 2009;4(2):143-63.

  61. Dallmann R, Okyar A, Lévi F. Dosing-time makes the poison: circadian regulation and pharmacotherapy. Trends in molecular medicine. 2016;22(5):430-45.

  62. Zhang P, Jin F, Li Z, Wu W, Li Y, Long J, et al. A randomized phase II trial of induction chemotherapy followed by cisplatin chronotherapy versus constant rate delivery combined with radiotherapy. Chronobiology international. 2018;35(2):240-48.

  63. Mohammadi D, Chronotherapy: treating cancer at the right time. Stroke. 2018;13:57.

  64. Tsuchiya Y, Ushijima K, Noguchi T, Okada N, Hayasaka J, Jinbu Y, et al. Influence of a dosing-time on toxicities induced by docetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study. Chronobiology international. 2018;35(2):289-94.

  65. Malek A. Experimental metastasis: Modeling and analysis. Experimental Metastasis: Modeling and Analysis. 2014[acceso: 16/08/2019]:1-210. Disponible en: https://www.springer.com/gp/book/9789400778344

  66. Rhodes A, Hillen T. A mathematical model for the immune-me diate d theory of metastasis. Pubmed. 2019[acceso: 16/08/2019];482. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31493486

  67. Kochanczyk M, Kocieniewski P, Koz 1owska E, Jaruszewicz-B1onska J, Sparta B, Pargett M, et al. Relaxation oscillations and hierarchy of feedbacks in MAPK signaling. Sci. Rep. 2017;7:38244. https://doi: 10.1038/srep38244

  68. Park J, Holmes WR, Lee SH, Kim HN, Kim DH, Kwak MK, et al. Mechanochemical feedback underlies coexistence of qualitatively distinct cell polarity patterns within diverse cell populations. Proc. Natl. Acad. Sci. 2017;114:5750-59.

  69. Ryu H, Chung M, Dobrzynski M, Fey D, Blum Y, Lee SS, et al. Frequency modulation of ERK activation dynamics rewires cell fate. Mol. Syst. Biol. 2015;11:838.

  70. Heinrich R, Neel BG, Rapoport TA. Mathematical models of protein kinase signal transduction. Mol. Cell. 2002;9:957-70.

  71. Jia D, Jolly MK, Tripathi SC, Den Hollander P, Huang B, Lu M, Celiktas M, et al. Distinguishing mechanisms underlying EMT tristability. Cancer Converg. 2017. https://doi: 10.1186/s41236-017-0005-8

  72. Jolly MK, Tripathi SC, Jia D, Mooney SM, Celiktas M, Hanash SM, et al. Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget. 2016;7:27067-084.

  73. MacLean A, Harrington H, Stumpf M, Hansen M. Epithelial-Mesenchymal Transition in Metastatic Cancer Cell Populations Affects Tumor Dormancy in a Simple Mathematical Model. Biomedicines. 2014,2(4):384-402.




2020     |     www.medigraphic.com